Filtered By:
Source: Cancer Control
Vaccination: Cancer Vaccines
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 661 results found since Jan 2013.
A Perspective on Implementation Outcomes and Strategies to Promote the Uptake of COVID-19 Vaccines
Front Health Serv. 2022 May 20;2:897227. doi: 10.3389/frhs.2022.897227. eCollection 2022.ABSTRACTRecent articles have highlighted the importance of incorporating implementation science concepts into pandemic-related research. However, limited research has been documented to date regarding implementation outcomes that may be unique to COVID-19 vaccinations and how to utilize implementation strategies to address vaccine program-related implementation challenges. To address these gaps, we formed a global COVID-19 implementation workgroup of implementation scientists who met weekly for over a year to review the available liter...
Source: Cancer Control - March 17, 2023 Category: Cancer & Oncology Authors: Meagan Pilar A Rani Elwy Larissa Lushniak Grace Huang Gabriella M McLoughlin Cole Hooley Nisha Nadesan-Reddy Brittney Sandler Mosa Moshabela Olakunle Alonge Elvin Geng Enola Proctor Source Type: research
Implementing behavioural science informed letter interventions to increase COVID-19 vaccination uptake in uncontactable London residents: a difference-in-difference study in London, UK
This study evaluated the impact of behavioural science-informed (BI) letters on vaccination uptake.METHODS: Unvaccinated residents of the Central London CCG who were deemed uncontactable (through text messaging and phone calls) were identified with the whole systems integrated care database. BI letters were sent to residents in the intervention CCG between May and June, 2021. Three neighbouring CCGs in London with similar non-responder data were used as control groups. A linear difference-in-difference analysis was undertaken to assess change in vaccine uptake rate across all four CCGs. Percentage point change was adjusted...
Source: Cancer Control - March 17, 2023 Category: Cancer & Oncology Authors: Sarah W Huf Lena Woldmann Roberto Fernandez Crespo Kate Grailey Bahram Hassanpourfard Matthew Chisambi Kirstie Black Joe Nguyen Bob Klaber Ara Darzi Source Type: research
The US President's Cancer Panel: A Model For Gathering Country-Level Input to Inform Cancer Control Policy and Program Initiatives
CONCLUSION: The US President's Cancer Panel highlights the importance of independent advisory bodies within a national cancer control program and of national leadership support for the cancer community. The structure and function of the Panel could be applicable in other settings worldwide.PMID:36921241 | DOI:10.1200/GO.22.00410
Source: Cancer Control - March 15, 2023 Category: Cancer & Oncology Authors: Lisa J Paradis Ann Chao Barbara K Rimer Abby B Sandler Kalina Duncan Mishka Kohli Cira Rachel Hanisch Source Type: research
Incidence and characterisation of post-COVID-19 symptoms in hospitalized COVID-19 survivors: A single centre, prospective observational cohort study to recognize the syndemic connotations in India
CONCLUSIONS: 60.8% of inpatients treated for COVID-19 had post-COVID-19 symptoms at 6 week's post- discharge from hospital. Incidence of post-COVID-19 syndrome in the cohort did not significantly differ across the mild, moderate and severe COVID-19 severity categories. Female sex and steroid administration during hospital stay were identified as predictors of persistence of post-COVID-19 symptoms at 6 weeks.PMID:36920842 | DOI:10.2196/40028
Source: Cancer Control - March 15, 2023 Category: Cancer & Oncology Authors: Dipu T Sathyapalan Chithira V Nair Merlin Moni Fabia Edathadathil Appukuttan A Preetha Prasanna Roshni Pushpa Raghavan Aveek Jayant Source Type: research
Pseudotyped Virus for Papillomavirus
Adv Exp Med Biol. 2023;1407:85-103. doi: 10.1007/978-981-99-0113-5_5.ABSTRACTPapillomavirus is difficult to culture in vitro, which limits its related research. The development of pseudotyped virus technology provides a valuable research tool for virus infectivity research, vaccine evaluation, infection inhibitor evaluation, and so on. Depending on the application fields, different measures have been developed to generate various kinds of pseudotyped papillomavirus. L1-based and L2-based HPV vaccines should be evaluated using different pseudotyped virus system. Pseudotyped papillomavirus animal models need high-titer pseud...
Source: Cancer Control - March 15, 2023 Category: Cancer & Oncology Authors: Xueling Wu Jianhui Nie Youchun Wang Source Type: research
Pregnancy-associated gynecological cancer in New South Wales, Australia 1994-2013: A population-based historical cohort study
CONCLUSIONS: The incidence of PAGC has not increased over time perhaps reflecting, in part, the effectiveness of cervical screening and early impacts of human papillomavirus vaccination programs in Australia. The higher rate of preterm birth among the gestational PAGC group is associated with adverse outcomes in babies born to these women.PMID:36915236 | DOI:10.1111/aogs.14530
Source: Cancer Control - March 14, 2023 Category: Cancer & Oncology Authors: Penelope Fotheringham Nadom Safi Zhouyang Li Antoinette Anazodo Marc Remond Andrew Hayen David Currow David Roder Nada Hamad Michael Nicholl Adrienne Gordon Jane Frawley Elizabeth A Sullivan Source Type: research
Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States
Vaccine. 2023 Mar 10:S0264-410X(23)00184-6. doi: 10.1016/j.vaccine.2023.02.049. Online ahead of print.ABSTRACTThe annual direct medical cost attributable to human papillomavirus (HPV) in the United States over the period 2004-2007 was estimated at $9.36 billion in 2012 (updated to 2020 dollars). The purpose of this report was to update that estimate to account for the impact of HPV vaccination on HPV-attributable disease, reductions in the frequency of cervical cancer screening, and new data on the cost per case of treating HPV-attributable cancers. Based primarily on data from the literature, we estimated the annual direc...
Source: Cancer Control - March 12, 2023 Category: Cancer & Oncology Authors: Patrick A Clay Trevor D Thompson Lauri E Markowitz Donatus U Ekwueme Mona Saraiya Harrell W Chesson Source Type: research
Oral lymphatic delivery of alpha-galactosylceramide and ovalbumin evokes anti-cancer immunization
J Control Release. 2023 Mar 10:S0168-3659(23)00177-3. doi: 10.1016/j.jconrel.2023.03.010. Online ahead of print.ABSTRACTWe developed an orally delivered nanoemulsion that induces cancer immunization. It consists of tumor antigen-loaded nano-vesicles carrying the potent invariant natural killer T-cell (iNKT) activator α-galactosylceramide (α-GalCer), to trigger cancer immunity by effectively activating both innate and adaptive immunity. It was validated that adding bile salts to the system boosted intestinal lymphatic transport as well as the oral bioavailability of ovalbumin (OVA) via the chylomicron pathway. To increase...
Source: Cancer Control - March 12, 2023 Category: Cancer & Oncology Authors: Prashant Pandey Seung Hyun Kim Laxman Subedi Khizra Mujahid Yebon Kim Young-Chang Cho Jung-Hyun Shim Ki-Taek Kim Seung-Sik Cho Jeong Uk Choi Jin Woo Park Source Type: research
Anti-cancer effect of COVID-19 vaccines in 4T1 mice models
This study is one of the first in vivo studies that try to show the impact of Sinopharm (S) and AstraZeneca (A) vaccines on breast cancer, the most common cancer among women worldwide.MATERIALS AND METHODS: Vaccination was performed with one and two doses of Sinopharm (S1/S2) or AstraZeneca (A1/A2) on the 4T1 triple-negative breast cancer (TNBC) mice model. The tumor size and body weight of mice were monitored every two days. After one month, mice were euthanized, and the existence of Tumor-infiltrating lymphocytes (TILs) and expression of the important markers in the tumor site was assessed. Metastasis in the vital organs...
Source: Cancer Control - March 12, 2023 Category: Cancer & Oncology Authors: Negar Deldadeh Shahpar Haghighat Zahra Omidi Ramin Sarrami-Foroushani Alireza Madjid Ansari Hassan Sanati Azadeh Azizi Farid Zayeri Flora Forouzesh Teunis B H Geijtenbeek Mohammad Amin Javidi Source Type: research
Loss of anti-spike antibodies following mRNA vaccination for COVID-19 among patients with multiple myeloma
CONCLUSIONS: Thus, even MM patients who respond adequately to vaccination are likely to require more frequent booster doses than the general population.PMID:36891732 | DOI:10.1002/cnr2.1803
Source: Cancer Control - March 9, 2023 Category: Cancer & Oncology Authors: Samuel D Stampfer Sean Bujarski Marissa-Skye Goldwater Scott Jew Bernard Regidor Haiming Chen Ning Xu Mingjie Li Eddie Fung Regina Swift Bethany Beatty Shahrooz Eshaghian James R Berenson Source Type: research
Rapid, sensitive, and specific detection of SARS-CoV-2 in nasopharyngeal swab samples of suspected patients using a novel one-step loop-mediated isothermal amplification (one-step LAMP) technique
CONCLUSIONS: The results showed that the One-Step LAMP assay is an efficient consistent technique for detecting SARS-CoV-2 among suspected individuals due to its simplicity, speed, low cost, sensitivity, and specificity. Therefore, it has great potential as a useful diagnostic tool for disease epidemic control, timely treatment, and public health protection, especially in poor and underdeveloped countries.PMID:36882699 | DOI:10.1186/s12866-023-02806-z
Source: Cancer Control - March 7, 2023 Category: Cancer & Oncology Authors: Sayyad Khanizadeh Asra Malekshahi Hooman Hanifehpour Mehdi Birjandi Shirzad Fallahi Source Type: research
Direct intranodal tonsil vaccination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac251
Nat Commun. 2023 Mar 7;14(1):1264. doi: 10.1038/s41467-023-36907-0.ABSTRACTHuman immunodeficiency virus (HIV) is a mucosally transmitted virus that causes immunodeficiency and AIDS. Developing efficacious vaccines to prevent infection is essential to control the epidemic. Protecting the vaginal and rectal mucosa, the primary routes of HIV entry has been a challenge given the significant compartmentalization between the mucosal and peripheral immune systems. We hypothesized that direct intranodal vaccination of mucosa associated lymphoid tissue (MALT) such as the readily accessible palatine tonsils could overcome this compa...
Source: Cancer Control - March 7, 2023 Category: Cancer & Oncology Authors: Jeffy G Mattathil Asisa Volz Olusegun O Onabajo Sean Maynard Sandra L Bixler Xiaoying X Shen Diego Vargas-Inchaustegui Marjorie Robert-Guroff Celia Lebranche Georgia Tomaras David Montefiori Gerd Sutter Joseph J Mattapallil Source Type: research
A mannosylated polymer with endosomal release properties for peptide antigen delivery
J Control Release. 2023 Mar 4:S0168-3659(23)00170-0. doi: 10.1016/j.jconrel.2023.03.004. Online ahead of print.ABSTRACTPeptide cancer vaccines have had limited clinical success despite their safety, characterization and production advantages. We hypothesize that the poor immunogenicity of peptides can be surmounted by delivery vehicles that overcome the systemic, cellular and intracellular drug delivery barriers faced by peptides. Here, we introduce Man-VIPER, a self-assembling (40-50 nm micelles), pH-sensitive, mannosylated polymeric peptide delivery platform that targets dendritic cells in the lymph nodes, encapsulates p...
Source: Cancer Control - March 6, 2023 Category: Cancer & Oncology Authors: Kefan Song Dinh Chuong Nguyen Tran Luu Omeed Yazdani Debashish Roy Patrick S Stayton Suzie H Pun Source Type: research
A research and development (R & amp;D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy
This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research cam...
Source: Cancer Control - March 4, 2023 Category: Cancer & Oncology Authors: Kristine A Moore Tabitha Leighton Julia T Ostrowsky Cory J Anderson Richard N Danila Angela K Ulrich Eve M Lackritz Angela J Mehr Ralph S Baric Norman W Baylor Bruce G Gellin Jennifer L Gordon Florian Krammer Stanley Perlman Helen V Rees Melanie Saville C Source Type: research
Reactive oxygen species-powered cancer immunotherapy: Current status and challenges
J Control Release. 2023 Mar 1:S0168-3659(23)00152-9. doi: 10.1016/j.jconrel.2023.02.040. Online ahead of print.ABSTRACTReactive oxygen species (ROS) are crucial signaling molecules that can arouse immune system. In recent decades, ROS has emerged as a unique therapeutic strategy for malignant tumors as (i) it can not only directly reduce tumor burden but also trigger immune responses by inducing immunogenic cell death (ICD); and (ii) it can be facilely generated and modulated by radiotherapy, photodynamic therapy, sonodynamic therapy and chemodynamic therapy. The anti-tumor immune responses are, however, mostly downplayed ...
Source: Cancer Control - March 3, 2023 Category: Cancer & Oncology Authors: Mengying He Mengyuan Wang Tao Xu Mengyao Zhang Huaxing Dai Chao Wang Dawei Ding Zhiyuan Zhong Source Type: research
